KRAS and cancer: Additional studies using mutant KRAS pancreatic and colorectal cells, as well as additional analyses using corresponding TCGA RNA-seq data, would be needed to determine the broader physiological relevance of our findings across other cancer types driven by oncogenic RAS signaling.